|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Molecular evolution of two duplicated CDPK genes CPK7 and CPK12 in grass species: A case study in wheat ( Triticum aestivum L.)显示文摘 | Shuaifeng Geng Yongliang Zhao Lichuan Tang Rongzhi Zhang Minghui Sun Hanzi Guo Xiuying Kong Aili Li Long Mao | 2011 | Gene2011，，2： | 1 |
| 2 | Circular RNA hsa_circ_0007444 inhibits ovarian cancer progression through miR-23a-3p/DICER1 axis显示文摘Ovarian cancer is the second leading cause of death in women with gynecological malignancy in China.Circular RNAs are a class of noncoding regulatory RNAs reported to be involved in cancer development and progression.Previous studies,including our own,have indicated that hsa_circ_0007444 is downregulated in ovarian cancer tissues.This study aims to elucidate the function and mechanism of hsa_circ_0007444 in ovarian cancer progression.The expression of hsa_circ_0007444 is determined by quantitative real-time PCR(qRT-PCR).Cell proliferation,invasion,migration and apoptosis are examined by cell counting-kit 8(CCK-8),transwell and flow cytometry assays.Tumor growth and metastasis are assessed in vivo using Balb/c nude mouse xenograft model and tail vein injection model.And the mechanism of action of hsa_circ_0007444 is analysed by RNA-binding protein immunoprecipitation(RIP),luciferase reporter and rescue assays.hsa_circ_0007444 is downregulated in ovarian cancer tissues and cell lines compared with that in normal ovarian tissues and normal epithelial cell line.Gain-and loss-of-function results indicate that hsa_circ_0007444 inhibits cell proliferation,invasion,migration and increases cell apoptosis of ovarian cancer cells in vitro,and inhibits tumor growth and lung metastasis in vivo.Mechanistically,hsa_circ_0007444 can interact with AGO2 and sponge miR-23a-3p,thereby upregulating DICER1 expression,which is an important tumor suppressor in ovarian cancer.And miR-23a-3p mimics can rescue the inhibitory effect of hsa_circ_0007444 on ovarian cancer cell proliferation,invasion and migration.Therefore,hsa_circ_0007444 can inhibit ovarian cancer progression through the hsa_circ_0007444/miR-23a-3p/DICER1 axis. | Min Zhang Yu Sun Hanzi Xu Yaqian Shi Rong Shen Fang Teng Juan Xu Xuemei Jia | 2023 | Acta Biochimica et Biophysica Sinica2023，55，4： | 0 |
| 3 | BGB-A445,a novel non-ligand-blocking agonistic anti-OX40 antibody,exhibits superior immune activation and antitumor effects in preclinical models显示文摘t OX40 is a costimulatory receptor that is expressed primarily on activated CD4+,CD8+,and regulatory T cells.The ligation of OX40 to its sole ligand OX40L potentiates T cell expansion,differentiation,and activation and also promotes dendritic cells to mature to enhance their cytokine production.Therefore,the use of agonistic anti-Ox40 antibodies for cancer immunotherapy has gained great interest.However,most of the agonistic anti-OX40 antibodies in the clinic are OX40L-competitive and show limited efficacy.Here,we discovered that BGB-A445,a non-ligand-competitive agonistic anti-OX40 antibody currently under clinical investigation,induced optimal T cell activation without impairing dendritic cell function.In addition,BGB-A445 dose-dependently and significantly depleted regulatory T cells in vitro and in vivo via antibody-dependent cellular cytotoxicity.In the MC38 syngeneic model established in humanized OX40 knock-in mice,BGB-A445 demonstrated robust and dose-dependent antitumor efficacy,whereas the ligand-competitive anti-Ox40 antibody showed antitumor efficacy characterized by a hook effect.Furthermore,BGB-A445 demonstrated a strong combination antitumor effect with an anti-PD-1 antibody.Taken together,our findings show that BGB-A445,which does not block OX40-OX40L interaction in contrast to clinical-stage anti-OX40 antibodies,shows superior immune-stimulating effects and antitumor efficacy and thus warrants further clinical investigation. | Beibei Jiang Tong Zhang Minjuan Deng Wei Jin Yuan Hong Xiaotong Chen Xin Chen Jing Wang Hongjia Hou Yajuan Gao Wenfeng Gong Xing Wang Haiying Li Xiaosui Zhou Yingcai Feng Bo Zhang Bin Jiang Xueping Lu Lijie Zhang Yang Li Weiwei Song Hanzi Sun Zuobai Wang Xiaomin Song Zhirong Shen Xuesong Liu Kang Li Lai Wangl Ye Liu | 2023 | Frontiers of Medicine2023，17，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员